FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020972495> ?p ?o ?g. }

• W3020972495 abstract "You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP01)1 Apr 2020MP01-09 LUTEOLIN SUPPRESSES SQUAMOUS DIFFERENTIATION OF BLADDER CANCER AND CANCER GROWTH VIA REGULATION OF MAMMALIAN TARGET OF RAPAMYCIN PATHWAY Keitaro Iida*, Taku Naiki, Aya Naiki-Ito, Takashi Nagai, Satoshi Nozaki, Toshiki Etani, Ryosuke Ando, Noriyasu Kawai, and Takahiro Yasui Keitaro Iida*Keitaro Iida* More articles by this author , Taku NaikiTaku Naiki More articles by this author , Aya Naiki-ItoAya Naiki-Ito More articles by this author , Takashi NagaiTakashi Nagai More articles by this author , Satoshi NozakiSatoshi Nozaki More articles by this author , Toshiki EtaniToshiki Etani More articles by this author , Ryosuke AndoRyosuke Ando More articles by this author , Noriyasu KawaiNoriyasu Kawai More articles by this author , and Takahiro YasuiTakahiro Yasui More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000815.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Luteolin is a natural flavonoid with strong antioxidative properties. The anti-cancer effect of luteolin in several cancers has been reported; however, little is known about its effect on bladder cancer. Here, we explored the effects of luteolin on bladder cancer. METHODS: Human urothelial carcinoma cell lines, T24 and 5637, were used. A WST-8 assay and western blotting were used to evaluate cell viability and protein signaling, respectively. Thioredoxin activity and reactive oxygen species (ROS) production were evaluated using thioredoxin and dichlorodihydrofluorescein diacetate assays, respectively. Furthermore, we examined the impact of a 20-week luteolin-rich diet on the growth of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)–induced bladder cancer in a rat model (luteolin concentrations were control, 20 ppm and 100 ppm; n=20, respectively). RESULTS: Luteolin induced a dose-dependent reduction in the number of viable cells; it also increased thioredoxin activity and decreased ROS production. Luteolin downregulated phospho-p70S6K and phospho-S6K (pS6), substrates of mammalian target of rapamycin (mTOR), which was reversed by the thioredoxin inhibitor, PX-12. This indicates luteolin inhibited the mTOR pathway by regulating thioredoxin and ROS. In an in vivo study, BBN-induced rat bladder cancer was inhibited by the oral administration of luteolin; the Ki67 labeling index and pS6 expression were also decreased. Further, both plasma and urine luteolin-3'-O-glucuronide concentrations were strongly associated with the Ki67 labeling index (r=0.31, -0.41, respectively) and the pS6 expression (r=-0.60, -0.62, respectively). Moreover, a significant decrease in the squamous differentiation of bladder cancer was attributed to plasma luteolin-3'-O-glucuronide concentrations (p<0.01). CONCLUSIONS: Luteolin may represent another natural product–derived therapeutic agent that acts against bladder cancer by up-regulating thioredoxin activity and inhibiting mTOR signaling. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e5-e5 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Keitaro Iida* More articles by this author Taku Naiki More articles by this author Aya Naiki-Ito More articles by this author Takashi Nagai More articles by this author Satoshi Nozaki More articles by this author Toshiki Etani More articles by this author Ryosuke Ando More articles by this author Noriyasu Kawai More articles by this author Takahiro Yasui More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3020972495 created "2020-05-13" @default.
• W3020972495 creator A5009980087 @default.
• W3020972495 creator A5026753886 @default.
• W3020972495 creator A5041675745 @default.
• W3020972495 creator A5057737749 @default.
• W3020972495 creator A5063282764 @default.
• W3020972495 creator A5067957872 @default.
• W3020972495 creator A5070315642 @default.
• W3020972495 creator A5076782173 @default.
• W3020972495 creator A5086715990 @default.
• W3020972495 date "2020-04-01" @default.
• W3020972495 modified "2023-09-27" @default.
• W3020972495 title "MP01-09 LUTEOLIN SUPPRESSES SQUAMOUS DIFFERENTIATION OF BLADDER CANCER AND CANCER GROWTH VIA REGULATION OF MAMMALIAN TARGET OF RAPAMYCIN PATHWAY" @default.
• W3020972495 doi "https://doi.org/10.1097/ju.0000000000000815.09" @default.
• W3020972495 hasPublicationYear "2020" @default.
• W3020972495 type Work @default.
• W3020972495 sameAs 3020972495 @default.
• W3020972495 citedByCount "0" @default.
• W3020972495 crossrefType "journal-article" @default.
• W3020972495 hasAuthorship W3020972495A5009980087 @default.
• W3020972495 hasAuthorship W3020972495A5026753886 @default.
• W3020972495 hasAuthorship W3020972495A5041675745 @default.
• W3020972495 hasAuthorship W3020972495A5057737749 @default.
• W3020972495 hasAuthorship W3020972495A5063282764 @default.
• W3020972495 hasAuthorship W3020972495A5067957872 @default.
• W3020972495 hasAuthorship W3020972495A5070315642 @default.
• W3020972495 hasAuthorship W3020972495A5076782173 @default.
• W3020972495 hasAuthorship W3020972495A5086715990 @default.
• W3020972495 hasBestOaLocation W30209724951 @default.
• W3020972495 hasConcept C121608353 @default.
• W3020972495 hasConcept C126322002 @default.
• W3020972495 hasConcept C143998085 @default.
• W3020972495 hasConcept C1491633281 @default.
• W3020972495 hasConcept C2776080593 @default.
• W3020972495 hasConcept C2778004101 @default.
• W3020972495 hasConcept C2779054382 @default.
• W3020972495 hasConcept C2780352672 @default.
• W3020972495 hasConcept C502942594 @default.
• W3020972495 hasConcept C53227056 @default.
• W3020972495 hasConcept C55493867 @default.
• W3020972495 hasConcept C62112901 @default.
• W3020972495 hasConcept C71924100 @default.
• W3020972495 hasConcept C86803240 @default.
• W3020972495 hasConcept C96232424 @default.
• W3020972495 hasConceptScore W3020972495C121608353 @default.
• W3020972495 hasConceptScore W3020972495C126322002 @default.
• W3020972495 hasConceptScore W3020972495C143998085 @default.
• W3020972495 hasConceptScore W3020972495C1491633281 @default.
• W3020972495 hasConceptScore W3020972495C2776080593 @default.
• W3020972495 hasConceptScore W3020972495C2778004101 @default.
• W3020972495 hasConceptScore W3020972495C2779054382 @default.
• W3020972495 hasConceptScore W3020972495C2780352672 @default.
• W3020972495 hasConceptScore W3020972495C502942594 @default.
• W3020972495 hasConceptScore W3020972495C53227056 @default.
• W3020972495 hasConceptScore W3020972495C55493867 @default.
• W3020972495 hasConceptScore W3020972495C62112901 @default.
• W3020972495 hasConceptScore W3020972495C71924100 @default.
• W3020972495 hasConceptScore W3020972495C86803240 @default.
• W3020972495 hasConceptScore W3020972495C96232424 @default.
• W3020972495 hasIssue "Supplement 4" @default.
• W3020972495 hasLocation W30209724951 @default.
• W3020972495 hasOpenAccess W3020972495 @default.
• W3020972495 hasPrimaryLocation W30209724951 @default.
• W3020972495 hasRelatedWork W2343693032 @default.
• W3020972495 hasRelatedWork W2344637265 @default.
• W3020972495 hasRelatedWork W2371146633 @default.
• W3020972495 hasRelatedWork W2609459726 @default.
• W3020972495 hasRelatedWork W2811050112 @default.
• W3020972495 hasRelatedWork W2909992919 @default.
• W3020972495 hasRelatedWork W2946712055 @default.
• W3020972495 hasRelatedWork W3026186115 @default.
• W3020972495 hasRelatedWork W3093726628 @default.
• W3020972495 hasRelatedWork W3214133144 @default.
• W3020972495 hasVolume "203" @default.
• W3020972495 isParatext "false" @default.
• W3020972495 isRetracted "false" @default.
• W3020972495 magId "3020972495" @default.
• W3020972495 workType "article" @default.